Project Checkpoint: Precision Immunotherapy via Remote Toxicity Monitoring
Lead Participant:
VESYNTA LIMITED
Abstract
**Who is Vesynta?**
A diagnostic enabled precision medicine company. We combine patient monitoring with clinical decision support to maximise therapeutic potential and de-risk drug treatment.
**Who are we helping?**
The 40% of cancer patients eligible for immunotherapy treatment
**What's the challenge?**
Immunotherapies are fast becoming standard of care in cancer management. Despite their promising performance, they have been shown to cause side effects in up to 70% of patients, including fever and mental disturbance, which can be fatal if left unmanaged. Detecting these side effects in a timely manner is a challenge, placing the patient at significant risk.
**Why is side effect monitoring a challenge?**
These side effects appear when the patient is at home. In the UK_,_ monitoring services look to measure specific blood markers that can confirm the occurrence of immunotherapy related side-effects. Unfortunately, these services require the patient to come into hospital, after the event has already happened.
**What do clinicians and patients want to improve?**
Clinicians are asking for real-time information on multiple marker levels following immunotherapy treatment, to detect side effects earlier.
Patients want to take control of their monitoring, with tools that empower them from their own home.
**Is this difficult?**
Changing the way healthcare monitors immunotherapy patients requires innovations that support remote measurements and side effect predictions. However, a solution that combines diagnostic, device engineering and pharmacology expertise could make this level of side-effect testing and management standard of care for all.
**What does Project Checkpoint achieve?**
An immunotherapy toxicity monitoring test, suitable for patient-use, paired with a prediction algorithm that helps detect side effects earlier and encourage personalised treatment interventions.
**Can we deliver?**
Our team includes world-leading engineers, pharmacologists, entrepreneurs, data scientists and diagnostic developers. NIHR-funding and private investment already supports development of our hospital-based drug monitoring platform. Checkpoint builds on these principles to revolutionise toxicity marker monitoring for patients at home.
**Who else benefits?**
Any setting that requires patient-led side effect monitoring. Checkpoint makes side effect monitoring more accessible and inclusive, creating opportunities to support development of immunotherapies during clinical trials to improve approved dose labels.
Ultimately, care providers, society and the wider economy will benefit from safer and more efficacious immunotherapy that improves long-term quality of life for the patient.
A diagnostic enabled precision medicine company. We combine patient monitoring with clinical decision support to maximise therapeutic potential and de-risk drug treatment.
**Who are we helping?**
The 40% of cancer patients eligible for immunotherapy treatment
**What's the challenge?**
Immunotherapies are fast becoming standard of care in cancer management. Despite their promising performance, they have been shown to cause side effects in up to 70% of patients, including fever and mental disturbance, which can be fatal if left unmanaged. Detecting these side effects in a timely manner is a challenge, placing the patient at significant risk.
**Why is side effect monitoring a challenge?**
These side effects appear when the patient is at home. In the UK_,_ monitoring services look to measure specific blood markers that can confirm the occurrence of immunotherapy related side-effects. Unfortunately, these services require the patient to come into hospital, after the event has already happened.
**What do clinicians and patients want to improve?**
Clinicians are asking for real-time information on multiple marker levels following immunotherapy treatment, to detect side effects earlier.
Patients want to take control of their monitoring, with tools that empower them from their own home.
**Is this difficult?**
Changing the way healthcare monitors immunotherapy patients requires innovations that support remote measurements and side effect predictions. However, a solution that combines diagnostic, device engineering and pharmacology expertise could make this level of side-effect testing and management standard of care for all.
**What does Project Checkpoint achieve?**
An immunotherapy toxicity monitoring test, suitable for patient-use, paired with a prediction algorithm that helps detect side effects earlier and encourage personalised treatment interventions.
**Can we deliver?**
Our team includes world-leading engineers, pharmacologists, entrepreneurs, data scientists and diagnostic developers. NIHR-funding and private investment already supports development of our hospital-based drug monitoring platform. Checkpoint builds on these principles to revolutionise toxicity marker monitoring for patients at home.
**Who else benefits?**
Any setting that requires patient-led side effect monitoring. Checkpoint makes side effect monitoring more accessible and inclusive, creating opportunities to support development of immunotherapies during clinical trials to improve approved dose labels.
Ultimately, care providers, society and the wider economy will benefit from safer and more efficacious immunotherapy that improves long-term quality of life for the patient.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| VESYNTA LIMITED | £767,304 | £ 498,748 |
People |
ORCID iD |
| Jugal Suthar (Project Manager) |